You are here

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Last updated on October 10, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-17 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of proven, probable, or possible invasive aspergillosis.

- Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.

- Chronic invasive aspergillosis.

- Receipt of antifungal treatment for more than 96 hours.

- Severe liver dysfunction.

NCT01188759
Pfizer
Withdrawn
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
Official Title  ICMJE A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years
Brief SummaryThis study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Aspergillosis
  • Invasive Pulmonary Aspergillosis
  • Neuroaspergillosis
Intervention  ICMJE
  • Drug: Voriconazole

    For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:

    Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.

    For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:

    Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.

    Voriconazole therapy is to be given for 6-12 weeks.

  • Drug: Anidulafungin

    Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).

    Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.

Study Arms  ICMJE
  • Experimental: Voriconazole and Anidulafungin Combination
    Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
    Interventions:
    • Drug: Voriconazole
    • Drug: Anidulafungin
  • Active Comparator: Voriconazole Monotherapy
    Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
    Intervention: Drug: Voriconazole
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: May 10, 2012)
0
Original Estimated Enrollment  ICMJE
 (submitted: August 24, 2010)
60
Estimated Study Completion Date  ICMJE August 2014
Estimated Primary Completion DateAugust 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of proven, probable, or possible invasive aspergillosis.
  • Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion Criteria:

  • Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
  • Chronic invasive aspergillosis.
  • Receipt of antifungal treatment for more than 96 hours.
  • Severe liver dysfunction.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 2 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location CountriesEgypt,   United States
 
Administrative Information
NCT Number  ICMJE NCT01188759
Other Study ID Numbers  ICMJE A1501095
Has Data Monitoring CommitteeYes
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateMay 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now